Persistent negative symptoms in individuals at Ultra High Risk for psychosis

[1]  R. Murray,et al.  Cortisol awakening response is decreased in patients with first-episode psychosis and increased in healthy controls with a history of severe childhood abuse , 2019, Schizophrenia Research.

[2]  P. McGorry,et al.  Clozapine use in early psychosis , 2018, Schizophrenia Research.

[3]  M. Lepage,et al.  Pathways to functional outcomes following a first episode of psychosis: The roles of premorbid adjustment, verbal memory and symptom remission , 2018, The Australian and New Zealand journal of psychiatry.

[4]  R. Murray,et al.  30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed Into the Developmental Risk Factor Model of Psychosis. , 2017, Schizophrenia bulletin.

[5]  J. Bobes,et al.  Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult Onset. , 2017, The Journal of clinical psychiatry.

[6]  A. Aleman,et al.  Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases , 2017, Schizophrenia Research.

[7]  I. Melle,et al.  Treatment of negative symptoms: Where do we stand, and where do we go? , 2017, Schizophrenia Research.

[8]  B. Nelson,et al.  The role of self-disturbances and cognitive biases in the relationship between traumatic life events and psychosis proneness in a non-clinical sample , 2017, Schizophrenia Research.

[9]  A. Malla,et al.  Psychological and psychosocial interventions for negative symptoms in psychosis: Systematic review and meta-analysis , 2017, British Journal of Psychiatry.

[10]  S. Galderisi,et al.  The current conceptualization of negative symptoms in schizophrenia , 2017, World psychiatry : official journal of the World Psychiatric Association.

[11]  E. Chen,et al.  Premorbid, clinical and cognitive correlates of primary negative symptoms in first-episode psychosis , 2016, Psychiatry Research.

[12]  R. Elliott,et al.  Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia: A Systematic Review and Meta-Analysis , 2016, Schizophrenia bulletin.

[13]  Peter B. Jones,et al.  Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population. , 2016, JAMA psychiatry.

[14]  D. Goff.  D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity , 2016, Current neuropharmacology.

[15]  P. McGuire,et al.  Stress Sensitivity, Aberrant Salience, and Threat Anticipation in Early Psychosis: An Experience Sampling Study , 2016, Schizophrenia bulletin.

[16]  D. Velligan,et al.  A case control study of association between cognition and functional capacity in schizophrenia , 2015, Schizophrenia Research.

[17]  S. Wood,et al.  Childhood maltreatment and transition to psychotic disorder independently predict long-term functioning in young people at ultra-high risk for psychosis , 2015, Psychological Medicine.

[18]  Jim Lewsey,et al.  Medical Statistics: A Guide to Data Analysis and Critical Appraisal , 2015 .

[19]  S. Galderisi,et al.  Neurobiological background of negative symptoms , 2015, European Archives of Psychiatry and Clinical Neuroscience.

[20]  R. Elliott,et al.  A systematic review and meta-analysis of exercise interventions in schizophrenia patients , 2015, Psychological Medicine.

[21]  K. Nuechterlein,et al.  Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8years later , 2015, Schizophrenia Research.

[22]  N. Andreasen.  Scale for the Assessment of Negative Symptoms , 2014 .

[23]  A. Üçok,et al.  Persistent negative symptoms after first episode schizophrenia: A 2-year follow-up study , 2014, Schizophrenia Research.

[24]  J. Read,et al.  From adversity to psychosis: pathways and mechanisms from specific adversities to specific symptoms , 2014, Social Psychiatry and Psychiatric Epidemiology.

[25]  S. Marder,et al.  Psychopharmacology of the negative symptoms: Current status and prospects for progress , 2014, European Neuropsychopharmacology.

[26]  Thomas Steckler,et al.  Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment , 2014, European Neuropsychopharmacology.

[27]  D. Javitt.  Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia , 2014, Current Treatment Options in Psychiatry.

[28]  E. Chen,et al.  The relationship of early premorbid adjustment with negative symptoms and cognitive functions in first-episode schizophrenia: A prospective three-year follow-up study , 2013, Psychiatry Research.

[29]  Hok Pan Yuen,et al.  Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. , 2013, JAMA psychiatry.

[30]  Cindy L. Hovington,et al.  Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms , 2013, Schizophrenia Research.

[31]  R. Buchanan,et al.  Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia , 2013, Schizophrenia Research.

[32]  R. Kahn,et al.  Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial , 2013, European Neuropsychopharmacology.

[33]  Julia M. Sheffield,et al.  Reduced gray matter volume in psychotic disorder patients with a history of childhood sexual abuse , 2013, Schizophrenia Research.

[34]  Cindy L. Hovington,et al.  Identifying persistent negative symptoms in first episode psychosis , 2012, BMC Psychiatry.

[35]  T. McGlashan,et al.  Risk factors for psychosis: impaired social and role functioning. , 2012, Schizophrenia bulletin.

[36]  Peter B. Jones,et al.  Is there a link between childhood trauma, cognition, and amygdala and hippocampus volume in first-episode psychosis? , 2012, Schizophrenia Research.

[37]  Tyrone D. Cannon,et al.  Negative symptoms in individuals at clinical high risk of psychosis , 2012, Psychiatry Research.

[38]  J. Read,et al.  Childhood Adversities Increase the Risk of Psychosis: A Meta-analysis of Patient-Control, Prospective- and Cross-sectional Cohort Studies , 2012, Schizophrenia bulletin.

[39]  M. Lam,et al.  Persistent negative symptoms in first-episode schizophrenia: A prospective three-year follow-up study , 2011, Schizophrenia Research.

[40]  C. Pantelis,et al.  Neurocognitive predictors of functional outcome two to 13years after identification as ultra-high risk for psychosis , 2011, Schizophrenia Research.

[41]  J. Mcdowd,et al.  The association between verbal memory, processing speed, negative symptoms and functional capacity in schizophrenia , 2011, Psychiatry Research.

[42]  J. Os,et al.  Childhood trauma and increased stress sensitivity in psychosis , 2011, Acta psychiatrica Scandinavica.

[43]  S. Wood,et al.  The psychosis threshold in Ultra High Risk (prodromal) research: Is it valid? , 2010, Schizophrenia Research.

[44]  S. Lewis,et al.  Predictors of 10-year outcome of first-episode psychosis , 2009, Psychological Medicine.

[45]  G. Krarup,et al.  Course of illness in a sample of 265 patients with first-episode psychosis—Five-year follow-up of the Danish OPUS trial , 2009, Schizophrenia Research.

[46]  G. Krarup,et al.  The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis , 2008, Psychological Medicine.

[47]  J. Peña,et al.  Processing speed mediates the relationship between verbal memory, verbal fluency, and functional outcome in chronic schizophrenia , 2008, Schizophrenia Research.

[48]  R. Buchanan,et al.  Persistent negative symptoms in schizophrenia: an overview. , 2007, Schizophrenia bulletin.

[49]  P. McGorry,et al.  Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. , 2007, The Journal of clinical psychiatry.

[50]  A. Georgi,et al.  Premorbid adjustment in schizophrenia — An important aspect of phenotype definition , 2007, Schizophrenia Research.

[51]  M. Lambert,et al.  Early Psychosis Prevention and Intervention Centre long‐term follow‐up study of first‐episode psychosis: methodology and baseline characteristics , 2007, Early intervention in psychiatry.

[52]  D. Javitt,et al.  Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia , 2006, Schizophrenia Research.

[53]  Brian Kirkpatrick,et al.  The NIMH-MATRICS consensus statement on negative symptoms. , 2006, Schizophrenia bulletin.

[54]  A. Yung,et al.  Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States , 2005 .

[55]  Belinda Barton,et al.  Medical Statistics: A Guide to SPSS, Data Analysis and Critical Appraisal , 2005 .

[56]  A. Malla,et al.  Can Patients at Risk for Persistent Negative Symptoms Be Identified During Their First Episode of Psychosis? , 2004, The Journal of nervous and mental disease.

[57]  Hok Pan Yuen,et al.  Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features , 2004, Schizophrenia Research.

[58]  Hok Pan Yuen,et al.  Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group , 2003, Schizophrenia Research.

[59]  M. Newcomb,et al.  Development and validation of a brief screening version of the Childhood Trauma Questionnaire. , 2003, Child abuse & neglect.

[60]  N. Haslam,et al.  Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill , 2003, Schizophrenia Research.

[61]  Dwight Dickinson,et al.  Independence and overlap among neurocognitive correlates of community functioning in schizophrenia , 2002, Schizophrenia Research.

[62]  S. Faraone,et al.  An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention , 2002, Schizophrenia Research.

[63]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[64]  J. Addington,et al.  Assessing Depression in Schizophrenia: The Calgary Depression Scale , 1993, British Journal of Psychiatry.

[65]  H. Goldman,et al.  Revising axis V for DSM-IV: a review of measures of social functioning. , 1992, The American journal of psychiatry.

[66]  W. Carpenter,et al.  Deficit and nondeficit forms of schizophrenia: the concept. , 1988, The American journal of psychiatry.

[67]  R. Murray,et al.  Is schizophrenia a neurodevelopmental disorder? , 1987, British medical journal.

[68]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[69]  E. Bleuler.  [Dementia praecox or the group of schizophrenias]. , 1968, Vertex.

[70]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[71]  C. Correll,et al.  The schizophrenia prodrome revisited: a neurodevelopmental perspective. , 2003, Schizophrenia bulletin.

[72]  Emil Kraepelin,et al.  Dementia praecox and paraphrenia , 2002 .

[73]  G C Patton,et al.  Monitoring and care of young people at incipient risk of psychosis. , 1996, Schizophrenia bulletin.

[74]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[75]  R. Reitan,et al.  The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation , 1993 .

[76]  S. C. Sohlberg,et al.  Social adjustment and cognitive performance of high-risk children. , 1985, Schizophrenia bulletin.

[77]  W T Carpenter,et al.  The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. , 1984, Schizophrenia bulletin.

[78]  R. Wyatt,et al.  Measurement of premorbid adjustment in chronic schizophrenia. , 1982, Schizophrenia bulletin.

[79]  J. Strauss,et al.  The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. , 1974, Schizophrenia bulletin.